| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NM1128 |
| P8608 | Fatcat ID | release_m2ddk4rydnholgxtholbnhilm4 |
| P698 | PubMed publication ID | 15502839 |
| P5875 | ResearchGate publication ID | 8214021 |
| P50 | author | Adrian V. S. Hill | Q22278197 |
| Sarah Gilbert | Q30513802 | ||
| Helen McShane | Q58870907 | ||
| Ansar Pathan | Q95950628 | ||
| Kris Huygen | Q32072525 | ||
| Helen Fletcher | Q42334206 | ||
| Sheila Keating | Q42769118 | ||
| P2093 | author name string | Clare R Sander | |
| P2860 | cites work | Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis | Q24537176 |
| Immunogenicity and protective efficacy of a tuberculosis DNA vaccine | Q44024302 | ||
| Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara | Q44138669 | ||
| A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans | Q45661091 | ||
| Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara | Q45722508 | ||
| Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans | Q45723463 | ||
| Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity | Q45734062 | ||
| A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection | Q45839569 | ||
| Purification, characterization and identification of a 32 kDa protein antigen of Mycobacterium bovis BCG. | Q46738626 | ||
| A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease | Q46950134 | ||
| Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes | Q47898136 | ||
| Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals | Q57081485 | ||
| Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells | Q73420709 | ||
| Correlates of protective immunity to Mycobacterium tuberculosis in humans | Q33956267 | ||
| Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis | Q34005845 | ||
| Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(+)- and CD4(+)-T-cell epitopes from antigen 85A. | Q34119135 | ||
| BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies | Q34125647 | ||
| Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis | Q34338450 | ||
| Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature | Q34349749 | ||
| Mapping of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis | Q34527217 | ||
| How can immunology contribute to the control of tuberculosis? | Q34572120 | ||
| Interferon-gamma and skin test responses of schoolchildren in southeast England to purified protein derivatives from Mycobacterium tuberculosis and other species of mycobacteria | Q39585291 | ||
| Evolution of epitope-specific memory CD4(+) T cells after clearance of hepatitis C virus. | Q43039389 | ||
| Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. | Q44022556 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virus | Q808 |
| antimycobacterial | Q2853298 | ||
| Vaccinia virus | Q1986297 | ||
| P304 | page(s) | 1240-1244 | |
| P577 | publication date | 2004-10-24 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans | |
| P478 | volume | 10 |
| Q58853010 | A Courageous Step Down the Road toward a New Tuberculosis Vaccine |
| Q28742450 | A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults |
| Q35830513 | A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults |
| Q42799618 | A booster vaccination with Mycobacterium bovis BCG does not increase the protective effect of the vaccine against experimental Mycobacterium ulcerans infection in mice |
| Q33999520 | A booster vaccine expressing a latency-associated antigen augments BCG induced immunity and confers enhanced protection against tuberculosis |
| Q40045492 | A comparison of IFNgamma detection methods used in tuberculosis vaccine trials |
| Q36673037 | A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults |
| Q35367108 | A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine |
| Q42265160 | A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity |
| Q37374704 | A multicistronic DNA vaccine induces significant protection against tuberculosis in mice and offers flexibility in the expressed antigen repertoire |
| Q35015787 | A mycolic acid-specific CD1-restricted T cell population contributes to acute and memory immune responses in human tuberculosis infection |
| Q43519813 | A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants |
| Q24657992 | A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers |
| Q97644982 | A novel formulation of Mtb72F DNA vaccine for immunization against tuberculosis |
| Q34290745 | A novel vaccine p846 encoding Rv3615c, Mtb10.4, and Rv2660c elicits robust immune response and alleviates lung injury induced by Mycobacterium infection |
| Q35036289 | A phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants |
| Q35889153 | A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults |
| Q38476599 | A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity |
| Q38711772 | A review of clinical models for the evaluation of human TB vaccines |
| Q36338571 | A side-by-side comparison of T cell reactivity to fifty-nine Mycobacterium tuberculosis antigens in diverse populations from five continents |
| Q57235920 | A tuberculosis vaccine based on phosphoantigens and fusion proteins induces distinct γδ and αβ T cell responses in primates |
| Q30384745 | Activation of cross-reactive mucosal T and B cell responses in human nasopharynx-associated lymphoid tissue in vitro by Modified Vaccinia Ankara-vectored influenza vaccines. |
| Q58827811 | Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection |
| Q36627619 | Advances in the Diagnosis, Treatment and Control of HIV Associated Tuberculosis |
| Q36482518 | Advances in tuberculosis vaccine strategies |
| Q38338183 | Aerosol immunisation for TB: matching route of vaccination to route of infection |
| Q33992101 | Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge |
| Q45233558 | Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers |
| Q64080157 | Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial |
| Q34092108 | An IL-15 adjuvant enhances the efficacy of a combined DNA vaccine against Brucella by increasing the CD8+ cytotoxic T cell response |
| Q51971392 | An IL-15 dependent CD8 T cell response to selected HIV epitopes is related to viral control in early-treated HIV-infected subjects. |
| Q81802920 | An action plan for tuberculosis in England |
| Q38041566 | An update on vaccines for tuberculosis - there is more to it than just waning of BCG efficacy with time |
| Q28243702 | Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis |
| Q57984714 | Apports de la génomique des mycobactéries a la définition de nouvelles stratégies thérapeutiques et vaccinales anti-tuberculeuses |
| Q36031187 | Assessment of the immune responses induced in cattle after inoculation of a Mycobacterium bovis strain deleted in two mce2 genes |
| Q39707019 | Bacillus Calmette-Guérin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles |
| Q33854478 | Baseline mycobacterial immune responses in HIV-infected adults primed with bacille Calmette-Guérin during childhood and entering a tuberculosis booster vaccine trial. |
| Q27008256 | Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination |
| Q37762830 | Boosting BCG to protect against TB. |
| Q37073334 | Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1. |
| Q36027530 | Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials |
| Q33303660 | Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials |
| Q34492614 | Boosting of cellular immunity against Mycobacterium tuberculosis and modulation of skin cytokine responses in healthy human volunteers by Mycobacterium bovis BCG substrain Moreau Rio de Janeiro oral vaccine. |
| Q38447094 | Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs |
| Q39473407 | Broad heparin-binding haemagglutinin-specific cytokine and chemokine response in infants following Mycobacterium bovis BCG vaccination |
| Q34229628 | Buruli ulcer |
| Q37145296 | CD4 T-cell-mediated heterologous immunity between mycobacteria and poxviruses |
| Q33428562 | CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination |
| Q34982062 | Cell-mediated immune responses in tuberculosis |
| Q31028998 | Cellular immune responses to nine Mycobacterium tuberculosis vaccine candidates following intranasal vaccination |
| Q51955817 | Challenge of developing new tuberculosis vaccines to generate life-long protective immunity. |
| Q44106019 | Chimpanzee adenoviral vectors as vaccines for outbreak pathogens |
| Q36347381 | Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults |
| Q35032532 | Cholera toxin enhances vaccine-induced protection against Mycobacterium tuberculosis challenge in mice |
| Q30362107 | Chronic helminth infections may negatively influence immunity against tuberculosis and other diseases of public health importance. |
| Q38156198 | Clinical applications of attenuated MVA poxvirus strain. |
| Q38092470 | Clinical development of Modified Vaccinia virus Ankara vaccines |
| Q36728808 | Combination vaccines: synergistic simultaneous induction of antibody and T-cell immunity |
| Q27309052 | Comparing adjuvanted H28 and modified vaccinia virus ankara expressingH28 in a mouse and a non-human primate tuberculosis model |
| Q33603206 | Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery |
| Q39585273 | Comparison of IFN-gamma responses to mycobacterial antigens as markers of response to BCG vaccination |
| Q54544918 | Comparison of immune responses induced in mice by vaccination with DNA vaccine constructs expressing mycobacterial antigen 85A and interleukin-21 and Bacillus Galmette-Guérin. |
| Q41122192 | Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects |
| Q36513366 | Confronting the scientific obstacles to global control of tuberculosis |
| Q38184579 | Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines |
| Q36315031 | Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. |
| Q24647051 | Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza |
| Q36449189 | Current and novel approaches to vaccine development against tuberculosis |
| Q36744717 | Current status of TB vaccines |
| Q37130796 | Current status of new tuberculosis vaccine in children |
| Q57203115 | DNA vaccines against mycobacterial diseases |
| Q36895737 | DNA vaccines against mycobacterial diseases |
| Q37672921 | Definition of CD4 Immunosignatures Associated with MTB. |
| Q36397581 | Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques |
| Q37530123 | Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccines |
| Q38262258 | Development of a new tuberculosis vaccine: is there value in the mucosal approach? |
| Q51742073 | Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccines. |
| Q36471916 | Development of cattle TB vaccines in the UK. |
| Q38096490 | Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. |
| Q33293376 | Development of new tuberculosis vaccines: a global perspective on regulatory issues |
| Q36492602 | Development of vaccines against bovine tuberculosis |
| Q35234118 | Development of vaccines against burkholderia pseudomallei |
| Q35024193 | Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus. |
| Q90621797 | Distinguishing Causation from Correlation in the Use of Correlates of Protection to Evaluate and Develop Influenza Vaccines |
| Q37956378 | Do new TB vaccines have a place in the Expanded Program on Immunization? |
| Q39935921 | Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI. |
| Q33908584 | Dual neonate vaccine platform against HIV-1 and M. tuberculosis |
| Q36154690 | Duration of immunity against Mycobacterium bovis following neonatal vaccination with bacillus Calmette-Guérin Danish: significant protection against infection at 12, but not 24, months. |
| Q35641132 | Early Kinetics of the HLA Class I-Associated Peptidome of MVA.HIVconsv-Infected Cells |
| Q34551322 | Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design |
| Q46768843 | Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study |
| Q28728311 | Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults |
| Q36313882 | Effects of DNA- and Mycobacterium bovis BCG-based delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis |
| Q43591184 | Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2. |
| Q38724073 | Emerging drugs and alternative possibilities in the treatment of tuberculosis |
| Q35184235 | Engineering new mycobacterial vaccine design for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG |
| Q84960715 | Enhanced T cell responsiveness to Mycobacterium bovis BCG r32-kDa Ag correlates with successful anti-tuberculosis treatment in humans |
| Q33389187 | Enhanced and enduring protection against tuberculosis by recombinant BCG-Ag85C and its association with modulation of cytokine profile in lung |
| Q84384783 | Enhanced protection against tuberculosis by vaccination with recombinant BCG over-expressing HspX protein |
| Q40190981 | Enhancement of Antituberculosis Immunity in a Humanized Model System by a Novel Virus-Vectored Respiratory Mucosal Vaccine. |
| Q53230123 | Envisioning future strategies for vaccination against tuberculosis. |
| Q30227121 | Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing |
| Q36237421 | Evaluation of Humoral Immunity to Mycobacterium tuberculosis-Specific Antigens for Correlation with Clinical Status and Effective Vaccine Development. |
| Q37671936 | Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination |
| Q41860986 | Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis |
| Q36826315 | Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques |
| Q34289930 | Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults |
| Q46318328 | Evidence for enhanced central memory priming by live Mycobacterium bovis BCG vaccine in comparison with killed BCG formulations |
| Q33440600 | Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies |
| Q34647872 | Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine. |
| Q47613327 | Exposure to Mycobacterium avium induces low-level protection from Mycobacterium bovis infection but compromises diagnosis of disease in cattle. |
| Q35023778 | Expression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus ankara enhances antiviral cellular and humoral immune responses |
| Q37907518 | Fact and fiction in tuberculosis vaccine research: 10 years later |
| Q40914004 | From AIDS to TB vaccines--A career in infectious diseases and translational vaccinology |
| Q27306708 | Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates |
| Q22252427 | Future Vaccination Strategies against Tuberculosis: Thinking outside the Box |
| Q98567938 | Genetic screening for the protective antigenic targets of BCG vaccination |
| Q38907507 | Global Efforts in the Development of Vaccines for Tuberculosis: Requirements for Improved Vaccines Against Mycobacterium tuberculosis |
| Q30355260 | HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development |
| Q38164196 | Harnessing local and systemic immunity for vaccines against tuberculosis |
| Q36899073 | Heterologous boost vaccines for bacillus Calmette-Guérin prime immunization against tuberculosis |
| Q37461371 | Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects |
| Q33825708 | Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant |
| Q26863391 | Host immune responses to mycobacterial antigens and their implications for the development of a vaccine to control tuberculosis |
| Q57112024 | How could we have better vaccines against tuberculosis? |
| Q38839838 | Human biomarkers: can they help us to develop a new tuberculosis vaccine? |
| Q92463453 | Identification of antigens presented by MHC for vaccines against tuberculosis |
| Q30408875 | Identification of antigens specific to non-tuberculous mycobacteria: the Mce family of proteins as a target of T cell immune responses |
| Q30945400 | Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis |
| Q33847573 | Immune correlates of acute Mycobacterium tuberculosis infection in household contacts in Kampala, Uganda |
| Q38606984 | Immune response induced by three Mycobacterium bovis BCG substrains with diverse regions of deletion in a C57BL/6 mouse model |
| Q41908519 | Immune responses induced in cattle by vaccination with a recombinant adenovirus expressing Mycobacterial antigen 85A and Mycobacterium bovis BCG |
| Q36213975 | Immune responses to tuberculosis in developing countries: implications for new vaccines |
| Q36628376 | Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations |
| Q45411590 | Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses |
| Q36679099 | Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1. |
| Q34643320 | Immunity, safety and protection of an Adenovirus 5 prime--Modified Vaccinia virus Ankara boost subunit vaccine against Mycobacterium avium subspecies paratuberculosis infection in calves |
| Q53644393 | Immunization with dendritic cells retrovirally transduced with mycobacterial antigen 85A gene elicits the specific cellular immunity including cytotoxic T-lymphocyte activity specific to an epitope on antigen 85A. |
| Q59351803 | Immunogenic cell death of dendritic cells following modified vaccinia virus Ankara infection enhances CD8 T cell proliferation |
| Q56774465 | Immunogenicity and protective efficacy of mycobacterial DNA vaccines incorporating plasmid-encoded cytokines against Mycobacterium bovis |
| Q37075418 | Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis |
| Q40308913 | Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3. |
| Q40304602 | Immunogenicity of Mycobacterium tuberculosis antigens in Mycobacterium bovis BCG-vaccinated and M. bovis-infected cattle |
| Q59151600 | Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants |
| Q34985591 | Immunological consequences of intragenus conservation of Mycobacterium tuberculosis T-cell epitopes |
| Q33518560 | Immunological memory transferred with CD4 T cells specific for tuberculosis antigens Ag85B-TB10.4: persisting antigen enhances protection |
| Q57598511 | Impfung gegen Tuberkulose |
| Q33324374 | Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boosting |
| Q34182371 | Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein |
| Q38192925 | In search of a new paradigm for protective immunity to TB |
| Q36786874 | In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination |
| Q58397026 | In vitro analysis of antigen induced T cell-monocyte conjugates by imaging flow cytometry |
| Q37051057 | In vitro levels of interleukin 10 (IL-10) and IL-12 in response to a recombinant 32-kilodalton antigen of Mycobacterium bovis BCG after treatment for tuberculosis |
| Q46277072 | In vivo evaluation of the efficacy of Sophora moorcroftiana alkaloids in combination with Bacillus Calmette-Guérin (BCG) treatment for cystic echinococcosis in mice |
| Q80155889 | Increased levels of interferon-gamma primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection |
| Q33919973 | Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin |
| Q39395640 | Individual-level factors associated with variation in mycobacterial-specific immune response: Gender and previous BCG vaccination status |
| Q40730694 | Induction of Specific CD8 T Cells against Intracellular Bacteria by CD8 T-Cell-Oriented Immunization Approaches |
| Q39323110 | Induction of an Immune-Protective T-Cell Repertoire With Diverse Genetic Coverage by a Novel Viral-Vectored Tuberculosis Vaccine in Humans |
| Q39028785 | Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag c |
| Q45418101 | Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity |
| Q33770851 | Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response |
| Q37335461 | Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with Mycobacterium bovis BCG. |
| Q92645553 | Insights and challenges in tuberculosis vaccine development |
| Q34975770 | Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis |
| Q51964364 | Intratracheal administration of third-generation lentivirus vector encoding MPT51 from Mycobacterium tuberculosis induces specific CD8+ T-cell responses in the lung. |
| Q42738250 | Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A |
| Q83312463 | Jenner reborn: a new vaccine institute |
| Q37290093 | Lessons for tuberculosis vaccines from respiratory virus infection. |
| Q50731289 | Liposomal delivery of lipoarabinomannan triggers Mycobacterium tuberculosis specific T-cells. |
| Q58834940 | Live tuberculosis vaccines based onphoPmutants: a step towards clinical trials |
| Q92645563 | Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial |
| Q64886404 | Longitudinal Evaluation of Humoral Immunity and Bacterial and Clinical Parameters Reveals That Antigen-Specific Antibodies Suppress Inflammatory Responses in Active Tuberculosis Patients. |
| Q36641634 | Longitudinal changes in CD4(+) T-cell memory responses induced by BCG vaccination of newborns |
| Q43996392 | Lymph node targeting of BCG vaccines amplifies CD4 and CD8 T-cell responses and protection against Mycobacterium tuberculosis |
| Q35022769 | M.tuberculosis mutants lacking oxygenated mycolates show increased immunogenicity and protective efficacy as compared to M. bovis BCG vaccine in an experimental mouse model |
| Q92339302 | MHC-restricted Ag85B-specific CD8+ T cells are enhanced by recombinant BCG prime and DNA boost immunization in mice |
| Q33430265 | MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques |
| Q64078255 | MVA85A vaccine to enhance BCG for preventing tuberculosis |
| Q94347757 | MVA85A vaccine to enhance BCG for preventing tuberculosis |
| Q37103536 | Macaque models of human infectious disease |
| Q43181626 | Members of the 30- to 32-kilodalton mycolyl transferase family (Ag85) from culture filtrate of Mycobacterium avium subsp. paratuberculosis are immunodominant Th1-type antigens recognized early upon infection in mice and cattle |
| Q36142504 | Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity |
| Q28223836 | Modified Vaccinia Virus Ankara |
| Q34605490 | Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells |
| Q35943471 | Modified vaccinia virus Ankara-based vaccine vectors induce apoptosis in dendritic cells draining from the skin via both the extrinsic and intrinsic caspase pathways, preventing efficient antigen presentation. |
| Q36498793 | Motivations and concerns about adolescent tuberculosis vaccine trial participation in rural Uganda: a qualitative study. |
| Q37559647 | Mucosal vaccines: novel advances in technology and delivery |
| Q47834561 | Multi-stage subunit vaccines against Mycobacterium tuberculosis: an alternative to the BCG vaccine or a BCG-prime boost? |
| Q37213915 | Mycobacteriosis in fishes: a review |
| Q35773915 | Mycobacterium bovis BCG Vaccination Induces Divergent Proinflammatory or Regulatory T Cell Responses in Adults |
| Q35909944 | Mycobacterium bovis Bacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease Control |
| Q38793308 | Mycobacterium indicus pranii as a booster vaccine enhances BCG induced immunity and confers higher protection in animal models of tuberculosis. |
| Q33626980 | Mycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining. |
| Q36154094 | Mycobacterium tuberculosis and the host response |
| Q38828636 | Mycobacterium tuberculosis infection and vaccine development. |
| Q35099713 | Mycobacterium tuberculosis-specific CD8+ T cells and their role in immunity |
| Q42737818 | New TB vaccine granted orphan drug status |
| Q35916176 | New TB vaccines: is there a requirement for CD8 T cells? |
| Q37766119 | New antituberculous drugs in development |
| Q37150326 | New drugs and vaccines for drug-resistant Mycobacterium tuberculosis infections |
| Q34172054 | New tuberculosis vaccines |
| Q37757648 | New vaccines for tuberculosis |
| Q34983688 | Newborn mice vaccination with BCG.HIVA²²² + MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routes |
| Q35099708 | Next generation: tuberculosis vaccines that elicit protective CD8+ T cells |
| Q57100109 | Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen |
| Q84193741 | Novel HIV-1 clade B candidate vaccines designed for HLA-B*5101(+) patients protected mice against chimaeric ecotropic HIV-1 challenge |
| Q58827719 | Novel Vaccination Strategies Against Tuberculosis |
| Q64375019 | Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults |
| Q34700682 | Novel prophylactic vaccine using a prime-boost method and hemagglutinating virus of Japan-envelope against tuberculosis |
| Q39842246 | Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis |
| Q33877458 | Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques |
| Q33801426 | Novel vaccination approaches to prevent tuberculosis in children |
| Q30363188 | Novel vaccination strategies against tuberculosis. |
| Q38194389 | Novel vaccine approaches for protection against intracellular pathogens. |
| Q34531535 | Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection |
| Q36562820 | Optimization of a Human Bacille Calmette-Guérin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity |
| Q33581724 | Paediatric tuberculosis |
| Q84992282 | Paradigm change in immune correlation: cellular or humoral? |
| Q35554825 | PedVacc 002: a phase I/II randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi |
| Q30378562 | Permutations of time and place in tuberculosis |
| Q33316559 | Persistence of the immune response induced by BCG vaccination |
| Q37034639 | Perspectives for a protective HIV-1 vaccine |
| Q34189865 | Perspectives on Clinical and Preclinical Testing of New Tuberculosis Vaccines |
| Q59382383 | Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epstein-Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma Patients |
| Q38435794 | Phosphatidylinositol di-mannoside and derivates modulate the immune response to and efficacy of a tuberculosis protein vaccine against Mycobacterium bovis infection. |
| Q44512209 | Plant-derived recombinant immune complexes as self-adjuvanting TB immunogens for mucosal boosting of BCG. |
| Q36909996 | Plasmid DNA and viral vector-based vaccines for the treatment of cancer |
| Q34699088 | Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. |
| Q37483591 | Potential cost-effectiveness of a new infant tuberculosis vaccine in South Africa--implications for clinical trials: a decision analysis |
| Q34395523 | Pre-clinical development of BCG.HIVA(CAT), an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG. |
| Q36403400 | Pre-erythrocytic malaria vaccines: towards greater efficacy |
| Q30381766 | Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. |
| Q36247723 | Preclinical testing of new vaccines for tuberculosis: a comprehensive review |
| Q38100044 | Preventive vaccines for tuberculosis |
| Q27024526 | Prime-boost approaches to tuberculosis vaccine development |
| Q39021341 | Prime-boost vaccination strategy with bacillus Calmette-Guérin (BCG) and liposomized alpha-crystalline protein 1 reinvigorates BCG potency |
| Q37049038 | Primer: making sense of T-cell memory. |
| Q36690291 | Progress towards an HIV vaccine based on recombinant bacillus Calmette-Guérin: failures and challenges |
| Q28485174 | Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic review |
| Q36329910 | Prospects for a novel vaccine against tuberculosis |
| Q28083377 | Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis? |
| Q33468422 | Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose |
| Q36096965 | Protection associated with a TB vaccine is linked to increased frequency of Ag85A-specific CD4(+) T cells but no increase in avidity for Ag85A |
| Q35301384 | Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate. |
| Q46630257 | Protective efficacy of recombinant (Ag85A) BCG Tokyo with Ag85A peptide boosting against Mycobacterium tuberculosis-infected guinea pigs in comparison with that of DNA vaccine encoding Ag85A. |
| Q35949758 | Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon |
| Q38444246 | Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. |
| Q36212676 | Pulmonary DNA vaccination: concepts, possibilities and perspectives |
| Q28084282 | Quest for correlates of protection against tuberculosis |
| Q42239687 | Recombinant Ag85B vaccine by taking advantage of characteristics of human parainfluenza type 2 virus vector showed Mycobacteria-specific immune responses by intranasal immunization. |
| Q34518560 | Recombinant BCG as a vaccine vehicle to protect against tuberculosis |
| Q42739629 | Recombinant HBHA boosting effect on BCG-induced immunity against Mycobacterium tuberculosis infection |
| Q30387447 | Recombinant Mycobacterium bovis BCG as an HIV vaccine vector |
| Q37191912 | Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses |
| Q42829229 | Recombinant murine gammaherpesvirus 68 (MHV-68) as challenge virus to test efficacy of vaccination against chronic virus infections in the mouse model |
| Q44080405 | Robust immune response elicited by a novel and unique Mycobacterium tuberculosis protein using an optimized DNA/protein heterologous prime/boost protocol |
| Q36980878 | Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A. |
| Q29620144 | Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial |
| Q34259027 | Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial. |
| Q33807147 | Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals |
| Q24647137 | Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa |
| Q36888036 | Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial. |
| Q33468451 | Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A |
| Q28473318 | Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa |
| Q45407829 | Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy |
| Q36287555 | Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial |
| Q34899535 | Schistosoma mansoni antigen Sm-p80: Prophylactic efficacy of a vaccine formulated in human approved plasmid vector and adjuvant (VR 1020 and alum). |
| Q40273775 | Sendai Virus Mucosal Vaccination Establishes Lung-Resident Memory CD8 T Cell Immunity and Boosts BCG-Primed Protection against TB in Mice |
| Q28649845 | Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A |
| Q36744991 | Should a new tuberculosis vaccine be administered intranasally? |
| Q47745185 | Strategies to Improve Vaccine Efficacy against Tuberculosis by Targeting Innate Immunity |
| Q41996442 | Successes and failures in human tuberculosis vaccine development. |
| Q37749889 | Swine influenza vaccines: current status and future perspectives |
| Q36252595 | Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis |
| Q34169888 | T cell reactivity against mycolyl transferase antigen 85 of M. tuberculosis in HIV-TB coinfected subjects and in AIDS patients suffering from tuberculosis and nontuberculous mycobacterial infections |
| Q36090185 | T cell vaccines for microbial infections |
| Q36799172 | T-cell activation is an immune correlate of risk in BCG vaccinated infants |
| Q37951575 | T-cell-inducing vaccines - what's the future |
| Q36470057 | TB vaccine strategies--what is needed to solve a complex problem? |
| Q37435926 | TB vaccines: current status and future perspectives |
| Q38392001 | TRANSVAC research infrastructure - Results and lessons learned from the European network of vaccine research and development |
| Q36189072 | Tailoring information provision and consent processes to research contexts: the value of rapid assessments |
| Q28740954 | Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A |
| Q30360726 | The TB pandemic: an old problem seeking new solutions. |
| Q90646281 | The Virulence of Different Vaccinia Virus Strains Is Directly Proportional to Their Ability To Downmodulate Specific Cell-Mediated Immune Compartments In Vivo |
| Q37548692 | The candidate TB vaccine, MVA85A, induces highly durable Th1 responses |
| Q35689134 | The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis |
| Q38116351 | The current state of tuberculosis vaccines |
| Q33637297 | The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial |
| Q37135865 | The induction and persistence of T cell IFN-gamma responses after vaccination or natural exposure is suppressed by Plasmodium falciparum |
| Q33659150 | The next 10 years for tuberculosis vaccines: do we have the right plans in place? |
| Q33950119 | The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults |
| Q38280134 | The present and future of tuberculosis vaccinations |
| Q26796600 | The re-emergency and persistence of vaccine preventable diseases |
| Q34261521 | The secreted lipoprotein, MPT83, of Mycobacterium tuberculosis is recognized during human tuberculosis and stimulates protective immunity in mice |
| Q37478271 | The study of novel DNA vaccines against tuberculosis: induction of pathogen-specific CTL in the mouse and monkey models of tuberculosis |
| Q36191944 | The success and failure of BCG - implications for a novel tuberculosis vaccine |
| Q36849770 | Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines |
| Q93052065 | Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection |
| Q34024201 | Toward Understanding the Essence of Post-Translational Modifications for the Mycobacterium tuberculosis Immunoproteome |
| Q30484783 | Toward novel vaccines against tuberculosis: current hopes and obstacles. |
| Q90439703 | Towards new TB vaccines |
| Q36736465 | Translational mini-review series on vaccines: Development and evaluation of improved vaccines against tuberculosis |
| Q79189338 | Tuberculosis in humans and animals: are we a threat to each other? |
| Q36960497 | Tuberculosis subunit vaccines: from basic science to clinical testing |
| Q89724634 | Tuberculosis vaccine development: from classic to clinical candidates |
| Q37213940 | Tuberculosis vaccine development: goals, immunological design, and evaluation |
| Q85075326 | Tuberculosis vaccine promises sterilizing immunity |
| Q53753719 | Tuberculosis vaccines - an update. |
| Q37878483 | Tuberculosis vaccines in clinical trials |
| Q22242669 | Tuberculosis vaccines: beyond bacille Calmette-Guerin |
| Q36458393 | Tuberculosis vaccines: current status and future prospects |
| Q37754908 | Tuberculosis vaccines: present and future |
| Q43105988 | Tuberculosis: A re-emerging enemy |
| Q36238724 | Tuberculosis: from genome to vaccine |
| Q36872636 | Tuberculosis: vaccine and drug development |
| Q34806664 | Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects |
| Q35913637 | Unique gene expression profiles in infants vaccinated with different strains of Mycobacterium bovis bacille Calmette-Guerin. |
| Q36407800 | Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization |
| Q41148159 | Using a prime and pull approach, lentivector vaccines expressing Ag85A induce immunogenicity but fail to induce protection against Mycobacterium bovis bacillus Calmette-Guérin challenge in mice |
| Q37229931 | Vaccination against paratuberculosis |
| Q34111604 | Vaccination with a Sindbis virus-based DNA vaccine expressing antigen 85B induces protective immunity against Mycobacterium tuberculosis |
| Q36570685 | Vaccine approaches to prevent tuberculosis |
| Q44862237 | Vaccine manufacturing: challenges and solutions |
| Q35947967 | Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding |
| Q51989059 | Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T cell responses. |
| Q36689438 | Vaccine-mediated immunity to experimental Mycobacterium tuberculosis is not impaired in the absence of Toll-like receptor 9 |
| Q26992233 | Vaccines against tuberculosis: where are we and where do we need to go? |
| Q35666220 | Vaccines displaying mycobacterial proteins on biopolyester beads stimulate cellular immunity and induce protection against tuberculosis |
| Q26996673 | Vaccines for TB: Lessons from the Past Translating into Future Potentials |
| Q36350586 | Vaccines for bovine tuberculosis: current views and future prospects. |
| Q36285657 | Vaccines for tuberculosis: novel concepts and recent progress |
| Q36557330 | Vaccines to prevent transmission of HIV-1 via breastmilk: scientific and logistical priorities |
| Q33912043 | Vaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptor |
| Q35571248 | Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. |
| Q36159950 | Vaccinology at the beginning of the 21st century |
| Q28768257 | Variable host-pathogen compatibility in Mycobacterium tuberculosis |
| Q37274874 | Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis |
| Q36802741 | Viral vector vaccines make memory T cells against malaria. |
| Q41812230 | Viral vectors for vaccine applications |
| Q38053069 | Virulence factors of the Mycobacterium tuberculosis complex |
| Q37646066 | Viruses as vaccine vectors for infectious diseases and cancer |
| Q82838981 | [Tuberculosis. Spain is different and the oblivion of the BCG vaccine] |
| Q33386020 | rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector |
Search more.